Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Jun 2026 · $123.3MThe company’s own SEC segment disclosure.
- ADMA Bio Manufacturing$123.3M100%
- Plasma Collection Centers$30.0K0%
ADMA Biologics, Inc. (ADMA) reported revenue of $114M in Q1 2026 (quarter ended Mar 31, 2026), down 0.3% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $45M (40% of revenue). For the full year FY2025, revenue was $510M (+20% year on year) and net income $147M. Its largest segment in Jun 2026 was ADMA Bio Manufacturing at $123M, 100% of the disclosed total, well ahead of Plasma Collection Centers at 0.0%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.